EUFOREA Consensus Meeting on Severe Uncontrolled Rhinitis 2024

Allergic rhinitis (AR) is the most common immunological disease affecting some 400 million people worldwide. It varies from being a minor nuisance to severe AR: a debilitating disease with a significant impact on quality of life (QoL). In addition, AR has the potential to develop several comorbidities including allergic asthma.

With novel knowledge and treatment options available there is a growing need to (re)define key definitions to enable communication across different specialties dealing with AR. The European Forum for Research and Education in Allergy and Airway Diseases (EUFOREA) will hold a meeting of experts from different specialities dealing with AR to find consensus on several definitions and disease states.

Building further on the consensus meetings on asthma (London, April 2023) and CRS (Brussels, June 2023), EUFOREA will now focus on AR as a disease for finding consensus on novel disease states and treatment targets.

This event is upon invitation!

To define the following:

• Control in AR
• Remission and cure in AR
• Recurrence/exacerbation of AR
• Disease Modification in AR
• Advise on the prevention of AR
• Shortcomings in AR care
• Suggestions to improve AR care
• Future ambitions in AR care